Mitchell Cancer Institute
Drug Discovery Research Center
Dr. Zhu has worked in the areas of carcinogenesis and cancer chemoprevention since 1996. His major research expertise is in the field of cyclic nucleotide signaling and phosphodiesterase isozymes that control tumor cell proliferation and apoptosis. Dr. Zhu received a Ph.D. in pharmacology from Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China in 1996. Dr. Zhu held a position as Assistant Professor for anti-tumor drug studies in Beijing Medical University, Chinese National Key Laboratory from 1996-1997. Dr. Zhu joined the University of South Alabama as a postdoctoral fellow from 1997-2002 and served as an independent investigator from 2002-2005. Dr. Zhu became a faculty member and a principal investigator in the Department of Pharmacology and Center for Lung Biology of University of South Alabama in 2005. Dr. Zhu held an Assistant Professor position from 2008-2011 and led several research projects in studies of the pharmacology and cell biology of tumor and endothelial cell models, which were supported by intramural and extramural funding from NIH and AHA resources. In November 2011, Dr. Zhu joined the Drug Discovery Research Center at the Mitchell Cancer Institute. Dr. Zhu’s studies are focused on understanding the basis of cell signaling transduction and compartmentalization for the cancer biology, chemotherapy and chemoprevention and the development of novel drugs with the potential for improved safety and efficacy in clinical application. Dr. Zhu has a special experience in tumorigenesis, chemoprevention, cancer biology, cyclic nucleotides and phosphodiesterase, especially in lung cancer area and related normal lung biology.
Cancer chemoprevention and anti-cancer drug development; Phosphodiesterases and cAMP/cGMP signaling in cancer biology; Intracellular signaling compartmentalization and anti-cancer therapy; Angiogenesis of cancer cells and normal tissues.